張麗娜,趙虎子,張永臣,趙蕾,王北,萬青,沈傳陸
(東南大學(xué)醫(yī)學(xué)院 病理學(xué)與病理生理學(xué)系,江蘇 南京 210009)
TC- 1癌蛋白高表達(dá)促進(jìn)人BT549乳腺癌細(xì)胞遷移
張麗娜,趙虎子,張永臣,趙蕾,王北,萬青,沈傳陸
(東南大學(xué)醫(yī)學(xué)院 病理學(xué)與病理生理學(xué)系,江蘇 南京210009)
[摘要]目的:構(gòu)建甲狀腺癌基因- 1(TC- 1)真核表達(dá)質(zhì)粒,觀察TC- 1癌蛋白高表達(dá)對(duì)人乳腺癌細(xì)胞遷移的影響。方法:用蛋白質(zhì)印跡方法檢測TC- 1癌蛋白在培養(yǎng)的人MCF- 7和BT549乳腺癌細(xì)胞中表達(dá);從MCF- 7細(xì)胞中提取總RNA,通過實(shí)時(shí)PCR(RT- PCR)擴(kuò)增人TC- 1 cDNA全長開放讀碼框架(ORF),并插入真核表達(dá)載體Flag- pcDNA3.0中構(gòu)建Flag- TC- 1- pcDNA3.0重組質(zhì)粒;經(jīng)限制性內(nèi)切酶和DNA測序鑒定后,該重組質(zhì)粒用于轉(zhuǎn)染BT549細(xì)胞,進(jìn)行蛋白質(zhì)印跡分析鑒定Flag- TC- 1融合蛋白表達(dá);進(jìn)行細(xì)胞劃痕實(shí)驗(yàn),觀察TC- 1對(duì)BT549細(xì)胞遷移的影響。結(jié)果:TC- 1蛋白在人MCF- 7乳腺癌細(xì)胞中顯著表達(dá),而BT549細(xì)胞中表達(dá)極低;人MCF- 7乳腺癌細(xì)胞TC- 1全長ORF的RT- PCR產(chǎn)物為337 bp;重組質(zhì)粒Flag- TC- 1- pcDNA3.0經(jīng)BamH Ⅰ和Xho Ⅰ雙酶切出現(xiàn)特征性的327 bp片段;DNA測序證實(shí)TC- 1全長ORF序列正確無誤,以正確的閱讀框架插入Flag- pcDNA3.0載體中。蛋白質(zhì)印跡結(jié)果顯示該重組質(zhì)粒轉(zhuǎn)染的BT549細(xì)胞表達(dá)的Flag- TC- 1融合蛋白可被抗Flag抗體特異性識(shí)別,分子質(zhì)量約為13.6 kDa,符合預(yù)期;劃痕實(shí)驗(yàn)結(jié)果顯示,高表達(dá)TC- 1的BT549細(xì)胞遷移性增加。結(jié)論:內(nèi)源性TC- 1蛋白在人BT549乳腺癌細(xì)胞中表達(dá)極低,F(xiàn)lag- TC- 1融合蛋白高表達(dá)促進(jìn)BT549細(xì)胞遷移。
[關(guān)鍵詞]甲狀腺癌基因- 1; 乳腺癌細(xì)胞; 真核表達(dá); 遷移
甲狀腺癌基因- 1(thyroid cancer- 1,TC- 1)是2000年從乳頭狀甲狀腺癌和正常甲狀腺組織的差異基因中篩選得到的,可以導(dǎo)致甲狀腺細(xì)胞惡性轉(zhuǎn)化[1],并且是惡性甲狀腺囊腫的標(biāo)志物[2]。TC- 1定位于8p11.2,其mRNA全長1 327 bp,開放閱讀框321 bp,編碼一種含106個(gè)氨基酸的固有無序蛋白(natively disordered protein);經(jīng)研究發(fā)現(xiàn),TC- 1在大腸癌[3]、肺癌[4]、舌鱗狀細(xì)胞癌[5]和胃癌[6]等腫瘤細(xì)胞中也有重要作用,促進(jìn)細(xì)胞的增殖分化,調(diào)節(jié)細(xì)胞的侵襲、轉(zhuǎn)移。乳腺癌的發(fā)展被普遍認(rèn)為與癌基因的擴(kuò)增及過表達(dá)有密切聯(lián)系,有研究發(fā)現(xiàn)TC- 1 mRNA在50%的乳腺癌細(xì)胞系中表達(dá)增加,其過表達(dá)能使正常乳腺上皮細(xì)胞惡性轉(zhuǎn)化為腫瘤細(xì)胞,但是TC- 1在乳腺癌細(xì)胞系中的作用機(jī)制尚不明確,對(duì)乳腺癌細(xì)胞遷移的影響還未見報(bào)道。
轉(zhuǎn)基因通常是指利用一定的載體和導(dǎo)入方法將外源基因?qū)爰?xì)胞,使其在靶細(xì)胞內(nèi)表達(dá)[7],轉(zhuǎn)基因技術(shù)為研究癌基因的生物學(xué)功能提供了重要基礎(chǔ)。本研究擬構(gòu)建TC- 1真核表達(dá)質(zhì)粒用于轉(zhuǎn)染乳腺癌細(xì)胞,以觀察TC- 1高表達(dá)對(duì)乳腺癌細(xì)胞相關(guān)的生物學(xué)功能變化影響,來研究TC- 1的功能及其在乳腺癌發(fā)生發(fā)展中的作用。
1材料與方法
1.1材料
凝膠回收試劑盒和質(zhì)粒小量提取試劑盒購于Axygen公司;限制性內(nèi)切酶(BamHⅠ、XhoⅠ)、T4 DNA連接酶、Trizol、反轉(zhuǎn)錄試劑盒、PCR試劑盒均購于大連TaKaRa生物有限公司;DNA Marker 和蛋白Marker 購于Fermentas公司;抗TC- 1抗體、抗Flag抗體和辣根過氧化物酶(HRP)標(biāo)記的羊抗兔IgG購于Santa Cruz 公司;增強(qiáng)型ECL發(fā)光試劑盒購自Thermo SIENTIFIC公司;大腸桿菌DH5α、質(zhì)粒Flag- pcDNA 3.0及人MCF- 7和BT549乳腺癌細(xì)胞均由本課題組保存。其他常規(guī)試劑均為國產(chǎn)分析純。
1.2TC- 1基因片段的RT- PCR擴(kuò)增
在用Trizol 試劑制備MCF- 7細(xì)胞總RNA后進(jìn)行反轉(zhuǎn)錄反應(yīng),以反轉(zhuǎn)錄的cDNA為模板,用上游引物(5′TAGGATCCATGAAAGCAAAGCGAAG 3′)和下游引物(5′TGCTCGAGTCAGTGAACTTTGATGG 3′)進(jìn)行PCR反應(yīng),擴(kuò)增出人TC- 1 cDNA完整開放讀碼框架(open reading frame,ORF)。PCR反應(yīng)條件為預(yù)變性94℃ 2min,1個(gè)循環(huán);變性98℃ 10s,退火56℃ 10s, 延伸72℃ 1min,35個(gè)循環(huán);總延伸72℃ 7min, 1個(gè)循環(huán)。將PCR擴(kuò)增產(chǎn)物經(jīng)1.2%瓊脂糖凝膠電泳,回收純化。
1.3Flag- pcDNA3.0/TC- 1重組質(zhì)粒的構(gòu)建
將回收純化的TC- 1RT- PCR產(chǎn)物用BamH Ⅰ和XhoⅠ雙酶切后,用T4 DNA連接酶與經(jīng)同樣雙酶切的Flag- pcDNA 3.0載體進(jìn)行連接,生成Flag- TC- 1融合蛋白真核表達(dá)質(zhì)粒Flag- TC- 1- pcDNA 3.0。將連接產(chǎn)物轉(zhuǎn)化E.coliDH5a 感受態(tài)細(xì)胞后置于搖床,37℃、250 r·min-1振蕩培養(yǎng)1 h,涂布于含100μg·ml-1氨芐青霉素的LB細(xì)菌培養(yǎng)板,37℃過夜培養(yǎng)。挑取單菌落培養(yǎng)并提取質(zhì)粒DNA,用BamH Ⅰ和XhoⅠ雙酶切后對(duì)陽性克隆進(jìn)行序列測定。
1.4細(xì)胞培養(yǎng)
人MCF7乳腺癌細(xì)胞被置于含10%胎牛血清、2nmol·L-1谷氨酰胺、100U·L-1青霉素和100μg·L-1鏈霉素的DMEM(高糖,GIBCO)培養(yǎng)基中;人BT549乳腺癌細(xì)胞被置于含10%胎牛血清的RPMI- 1640(GIBCO)培養(yǎng)基中,于體積分?jǐn)?shù)為5%CO2、37℃ 培養(yǎng),待細(xì)胞80%~90%基本融合后傳代培養(yǎng)。
1.5細(xì)胞轉(zhuǎn)染
將對(duì)數(shù)生長期的細(xì)胞以每孔3×105個(gè)細(xì)胞接種于35mm培養(yǎng)皿或6孔培養(yǎng)板中過夜培養(yǎng)18~20h,使細(xì)胞融合度達(dá)到90%左右;棄原培養(yǎng)液,重新加入新鮮的DMEM完全培養(yǎng)液1ml,繼續(xù)培養(yǎng)0.5~1h;分別用50μl無血清的DMEM培養(yǎng)液稀釋1μg質(zhì)粒DNA和3μl LipoD293TM后,將LipoD293TM稀釋液加入到質(zhì)粒DNA稀釋液中,混勻后常溫下孵育15min;將質(zhì)粒DNA- LipoD293TM混合物滴加到上述含細(xì)胞的35mm 培養(yǎng)皿或6孔培養(yǎng)板的孔中,混勻后培養(yǎng)12h;吸去轉(zhuǎn)染混合液,加入DMEM完全培養(yǎng)液繼續(xù)培養(yǎng)18~20h, 然后已轉(zhuǎn)染的細(xì)胞被用于各個(gè)實(shí)驗(yàn)。
1.6蛋白質(zhì)印跡檢測
用冰冷PBS溶液洗轉(zhuǎn)染后的細(xì)胞2遍,加入100μl RIPA細(xì)胞裂解液。收集細(xì)胞裂解物置冰浴孵育10 min,然后4℃、12 000 g離心10 min,取上清液進(jìn)行SDS(十二烷基硫酸鈉)- 聚丙烯酰胺凝膠電泳和轉(zhuǎn)膜。分別用抗TC- 1抗體、抗Flag抗體和抗GAPDH抗體及相應(yīng)的HRP標(biāo)記的二抗檢測TC- 1、Flag- TC- 1和GAPDH(作為上樣對(duì)照),然后與增強(qiáng)型化學(xué)發(fā)光底物反應(yīng),以顯示各蛋白條帶。
1.7劃痕實(shí)驗(yàn)
以Flag- pcDNA 3.0空載體質(zhì)粒為對(duì)照,用Flag- TC- 1- pcDNA 3.0轉(zhuǎn)染BT549細(xì)胞,20h后用20μl微量移液器槍頭在培養(yǎng)皿底部作“1”字形劃痕;用37℃預(yù)溫的PBS洗細(xì)胞3遍以洗去脫落的細(xì)胞及其碎片,加入1ml含2%FBS的RPMI 1640培養(yǎng)液,置于37℃、體積分?jǐn)?shù)5%的CO2飽和濕度培養(yǎng)箱中培養(yǎng),于0、12和24h時(shí)間點(diǎn)分別用顯微鏡(×100)觀察并拍攝記錄劃痕邊緣細(xì)胞遷移變化。
2結(jié)果
2.1內(nèi)源性TC- 1癌蛋白在人MCF- 7和BT549乳腺癌細(xì)胞中的差異性表達(dá)
已有研究表明TC- 1 mRNA在約50%的乳腺癌病人癌組織中表達(dá)增加[8],但TC- 1在人MCF- 7和BT549乳腺癌細(xì)胞中的表達(dá)尚不清楚。我們用抗TC- 1抗體檢測了MCF- 7和BT549細(xì)胞中內(nèi)源性TC- 1癌蛋白表達(dá)水平,發(fā)現(xiàn)TC- 1蛋白在MCF7細(xì)胞中顯著高表達(dá),相反在BT549細(xì)胞中表達(dá)極低(圖1),在過度曝光時(shí),可見微弱TC- 1蛋白條帶(結(jié)果未顯示)。這些結(jié)果表明人MCF- 7和BT549乳腺癌細(xì)胞差異性表達(dá)內(nèi)源性TC- 1癌蛋白。

圖1人MCF7和BT549乳腺癌細(xì)胞差異性表達(dá)內(nèi)源性TC- 1癌蛋白
Fig 1Differential expression of endogenous TC- 1 oncoprotein in human MCF7 and BT549 breast cancer cells
2.2Flag- TC- 1- pcDNA3.0重組質(zhì)粒的構(gòu)建和表達(dá)
RT- PCR擴(kuò)增得到的TC- 1 cDNA完整ORF,經(jīng)瓊脂糖凝膠電泳后出現(xiàn)1條337 bp 左右的DNA條帶(圖2),大小與預(yù)期相符。將該RT- PCR產(chǎn)物用BamH Ⅰ和XhoⅠ雙酶切后插入經(jīng)同樣雙酶切的真核表達(dá)載體Flag- pcDNA 3.0 質(zhì)粒中,生成重組質(zhì)粒Flag- TC- 1- pcDNA 3.0。該質(zhì)粒經(jīng)BamHⅠ和XhoⅠ雙酶切時(shí)出現(xiàn)327 bp特征性片段(圖3)。DNA序列測定證實(shí)序列無誤(結(jié)果未顯示)。

M.DNA分子質(zhì)量標(biāo)記;TC- 1.TC- 1 PCR產(chǎn)物
圖2TC- 1的RT- PCR產(chǎn)物
M.DNA ladder;TC- 1.TC- 1 PCR products
Fig 2RT- PCR products of TC- 1

M.DNA分子質(zhì)量標(biāo)記;1、2、3.Flag- TC- 1- pcDNA 3.0質(zhì)粒單克隆菌落的編號(hào)
圖3Flag- pcDNA 3.0/TC- 1重組質(zhì)粒酶切鑒定
M.DNA ladder;1、2、3.number of FLAG- TC- 1- pcDNA3.0 coloniesFig 3Identification of recombinant plasmid Flag- TC- 1- pcDNA 3.0 by restriction enzyme digestion
以Flag- pcDNA 3.0空載體為對(duì)照,用Flag- TC- 1- pcDNA 3.0轉(zhuǎn)染BT549細(xì)胞后收集細(xì)胞裂解物,用抗Flag抗體進(jìn)行蛋白質(zhì)印跡實(shí)驗(yàn),結(jié)果顯示Flag- TC- 1- pcDNA 3.0 轉(zhuǎn)染細(xì)胞在約13.6 kDa蛋白分子質(zhì)量處出現(xiàn)蛋白表達(dá)條帶,符合預(yù)期;而空載體轉(zhuǎn)染的細(xì)胞未見蛋白條帶(圖4)。這些結(jié)果表明,F(xiàn)lag- TC- 1- pcDNA 3.0重組質(zhì)粒能在人BT549乳腺導(dǎo)管癌細(xì)胞中表達(dá)Flag- TC- 1融合蛋白。

圖4Flag- TC- 1融合蛋白在人BT549乳腺導(dǎo)管癌細(xì)胞中的表達(dá)Fig 4Expression of Flag- TC- 1 fusion protein in human BT549 breast ductal carcinoma cells
2.3高表達(dá)TC- 1癌蛋白的人BT549乳腺導(dǎo)管癌細(xì)胞遷移性增加
TC- 1高表達(dá)能使人正常乳腺上皮細(xì)胞惡性轉(zhuǎn)化為腫瘤細(xì)胞,但對(duì)乳腺癌細(xì)胞遷移性是否有影響還未見報(bào)道。我們分別用Flag- pcDNA 3.0空載體和Flag- TC- 1- pcDNA 3.0重組質(zhì)粒轉(zhuǎn)染人BT549乳腺導(dǎo)管癌細(xì)胞,進(jìn)行劃痕實(shí)驗(yàn)。結(jié)果顯示,在劃痕后12 h空載體轉(zhuǎn)染的BT549乳腺導(dǎo)管癌細(xì)胞的劃痕大小幾乎無明顯變化,而TC- 1轉(zhuǎn)染乳腺癌細(xì)胞的劃痕已縮小近50%;24 h后空載體對(duì)照細(xì)胞的劃痕大小僅縮小不到1/3,而高表達(dá)TC- 1的BT549癌細(xì)胞的劃痕已接近消失(圖5)。這些結(jié)果表明,TC- 1高表達(dá)增強(qiáng)人BT549乳腺導(dǎo)管癌細(xì)胞的遷移性。
3討論
研究發(fā)現(xiàn),TC- 1在乳頭狀甲狀腺癌組織中表達(dá)增高,并證實(shí)過表達(dá)TC- 1的正常甲狀腺細(xì)胞增殖迅速,無錨定依賴生長良好,較未導(dǎo)入TC- 1的甲狀腺細(xì)胞凋亡率明顯降低[9]。自2000年在甲狀腺癌組織中發(fā)現(xiàn)TC- 1高表達(dá)后[10],人們發(fā)現(xiàn)TC- 1在許多腫瘤組織中都過表達(dá),而且在正常組織中,尤其是心、肝、肺和胎盤也有表達(dá),并參與細(xì)胞周期的調(diào)控、基因轉(zhuǎn)錄和翻譯。近幾年的研究表明,TC- 1在胃癌、肺癌等細(xì)胞株中,正向調(diào)控Wnt/β- 連環(huán)蛋白信號(hào)傳導(dǎo)通路,上調(diào)此信號(hào)通路中的許多靶基因,包括血管內(nèi)皮生長因子、G1/S- 特異性周期蛋白- D1、基質(zhì)金屬蛋白酶7、c- myc原癌基因等,而這些靶基因編碼多種腫瘤相關(guān)蛋白[11],已經(jīng)被證實(shí)與腫瘤的增殖、侵襲、遷移等行為密切相關(guān)。Yang等[8]對(duì)7個(gè)乳腺癌細(xì)胞系及100例乳腺癌組織進(jìn)行系統(tǒng)的研究,證實(shí)了TC- 1等基因定位于8p11.2,該染色體區(qū)域在乳腺癌發(fā)生發(fā)展具有重要作用;TC- 1在人乳腺上皮細(xì)胞中具有惡性轉(zhuǎn)化功能。
2011年St Gallen根據(jù)(雌激素受體)ER、(孕激素受體)PR和(人表皮生長因子受體- 2)Her2 3種分子標(biāo)志物的表達(dá)將乳腺癌進(jìn)行分子分型[12],發(fā)現(xiàn)MCF7細(xì)胞是ER、PR和Her2陽性,BT549細(xì)胞是ER、PR和Her2 陰性,而三陰性乳腺癌遷移性強(qiáng),內(nèi)分泌治療和分子靶向治療無效。本實(shí)驗(yàn)發(fā)現(xiàn),TC- 1在人MCF- 7乳腺癌細(xì)胞中高表達(dá),而在人BT549乳腺導(dǎo)管癌細(xì)胞中表達(dá)極低,這種現(xiàn)象可能是由于MCF7細(xì)胞中抑制遷移的細(xì)胞學(xué)或組織學(xué)因素多,BT49細(xì)胞中促進(jìn)遷移的力量比較大導(dǎo)致的。我們用RT- PCR方法從MCF- 7細(xì)胞中擴(kuò)增出TC- 1 cDNA完整ORF,構(gòu)建了TC- 1真核表達(dá)質(zhì)粒Flag- TC- 1- pcDNA 3.0,用該質(zhì)粒轉(zhuǎn)染BT549細(xì)胞后發(fā)現(xiàn),TC- 1高表達(dá)增強(qiáng)人乳腺癌細(xì)胞遷移性。

圖5高表達(dá)TC- 1癌蛋白的人BT549乳腺癌細(xì)胞劃痕實(shí)驗(yàn)分析
Fig 5Scratch- wound assays of human BT549 breast cancer cells overexpressing TC- 1 protein
[參考文獻(xiàn)]
[1] CHUA E L,YOUNG L,WU W M,et al.Cloning of TC- 1(C8orf4),a novel gene found to be over- expressed in thyroid cancer [J].Genomics,2000,69:342- 347.
[2] De MELO MARTINS P C,PARISE JUNIOR O,PEREIRA HORS C,et al.C8orf4 / TC- 1(Thyroid Cancer- 1) Gene Expression in Thyroid Cancer and Goiter[J].Original Paper,2007,69(2):127- 130.
[3] FRIEDMAN J B,BRUNSCHWIG E B,PLATER P,et al.C8orf4 is a transforming growth factor B induced transcript downregulated in metastatic colon cancer[J].Int J Cancer,2004,111(1):72- 75.
[4] SU K,HUANG L J,LI W H,et al.TC- 1(c8orf4) enhances aggressive biologic behavior in lung cancer through the Wnt/b- catenin pathway[J].Journal of Surgical Research,2013,185(1):255- 263.
[5] ZHANG P,CAO H Y,BAI L L,et al.The high expression of TC1(C8orf4) was correlated with the expression of β- catenin and cyclin D1 and the progression of squamous cell carcinomas of the tongue[J].Tumor Biol,2015,36(9):7061- 7067.
[6] KIM B,KOO H,YANG S,et al.TC- 1(C8orf4) correlates with Wnt/ beta- catenin target genes and aggressive biological behavior in gastric cancer[J].Clin Cancer Res,2006,12(11):3541- 3548.
[7] 高峰,鄭聲琴,張宇偉,等.RegⅣ基因在結(jié)直腸癌細(xì)胞系中的mRNA表達(dá)及pcDNA- RegⅣ的構(gòu)建與轉(zhuǎn)染[J].東南大學(xué)學(xué)報(bào):醫(yī)學(xué)版,2006,25(3):147- 150.
[8] YANG Z Q,MOFFA A B,HADDAD R,et al.Transforming properties of TC- 1 in human breast cancer:interaction with FGFR- 1 AND beta- catinin signaling pathways[J].Fat J Cancer,2007,121(6):1265- 1273.
[9] MOKHTARZADA S,YU C,BRICKENDEN A,et al.Structural characterization of partially disordered human Chibby:insights into its function in the Wnt- signalingpathway[J].Biochemistry,2011,50(5):715- 726.
[10] CHUA E L,YOUNG L,WU W M, et al.Cloning of TC- 1(C8orf4),a novel gene found to be overexpressed in thyroid cancer [J].Genomics,2000,69(3):342- 347.
[11] 張春勇,朱海濤,謝敏.human NF- κB miRNA 干擾載體的構(gòu)建[J].現(xiàn)代醫(yī)學(xué),2012,40(4):393- 397.
[12] GOLDHISCH A,WOOD W C,COATES A S,et al.Strategies for subtypes- dealing with the diversity of breast cancer:highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J].Ann Oncol,2011,22(8):1736- 1747.
TC- 1 overexpression stimulates migration of human BT549 breast cancer cells
ZHANG Li- na,ZHAO Hu- zi,ZHANG Yong- chen,ZHAO Lei,WANG Bei,WAN Qing,SHEN Chuan- lu
(DepartmentofPathologyandPathophysiology,MedicalSchoolofSoutheastUniverstiy,Nanjing210009,China)
[Abstract]Objective: To investigate impact of thyroid cancer- 1(TC- 1) overexpression on the migration of human breast cancer cells after construction of the TC- 1 eukaryotic expression plasmid. Methods: Western blot was used to detect the TC- 1 expression in the cultured human MCF- 7 and BT549 breast cancer cells. Subsequently, the total RNA was extracted from the MCF- 7 cells, and the full length open reading frame(ORF) of TC- 1 cDNA was amplified by RealTime- PCR(RT- PCR) and then inserted into the eukaryotic expression vector Flag- pcDNA3.0 to generate recombinant plasmid Flag- TC- 1- pcDNA3.0. After identification by restriction enzyme digestion and DNA sequencing, the recombinant plasmid was transfected into the BT549 cells. The expression of Flag- TC- 1 fusion protein in the transfected cells was monitored by using Western blot. Scratch- wound assays were performed to observe impact of TC- 1 overexpression on migration of the BT549 cells. Results: Human MCF- 7 breast cancer cells expressed TC- 1 protein at a high level while the protein level was extremely low in BT549 cells. The RT- PCR product of TC- 1 from the MCF- 7 cells was 337 bp, which was consistant with the full length ORF of the gene. The recombinant plasmid Flag- TC- 1- pcDNA3.0 was identified with double digestion using BamH Ⅰ and Xho Ⅰ, in which a characteristic fragment of 327 bp appeared, and the full length ORF of TC- 1 cDNA sequence was confirmed by direct automated sequencing. After the BT549 cells were transfected with the recombinant plasmid, Flag- TC- 1 fusion protein expressed in the cells was specifically recognized by anti- Flag antibody. As expected, the molecular weight of the fusion protein is about 13.6 kDa. Then, the scratch- wound assays were performed in the transfected cells and showed that overexpression of TC- 1 increased migration of the BT549 cells. Conclusions: The endogenous TC- 1 protein level is extremely low in human BT549 breast cancer cells and overexpression of Flag- TC- 1 fusion protein stimulates migration of the cells.
[Key words]thyroid cancer- 1 gene; breast cancer cells; eukaryotic expression; migration
[收稿日期]2015- 12- 30[修回日期] 2016- 02- 05
[基金項(xiàng)目]國家自然科學(xué)基金資助項(xiàng)目(81272261)
[作者簡介]張麗娜(1988-),女,山東聊城人,在讀碩士研究生。E- mail:imzhanglina@126.com
[通信作者]沈傳陸E- mail:shencl37@163.com
[中圖分類號(hào)]R736.1; R737.9
[文獻(xiàn)標(biāo)識(shí)碼]A
[文章編號(hào)]1671- 6264(2016)03- 0314- 06
doi:10.3969/j.issn.1671- 6264.2016.03.005
[引文格式] 張麗娜,趙虎子,張永臣,等.TC- 1癌蛋白高表達(dá)促進(jìn)人BT549乳腺癌細(xì)胞遷移[J].東南大學(xué)學(xué)報(bào):醫(yī)學(xué)版,2016,35(3):314- 319.
·論著·